Sanofi SA vs United Microelectronics Corp — how do they compare? Sanofi SA trades at $40.05 (market cap $95.18B), while United Microelectronics Corp trades at $22.89 (market cap $58.02B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and United Microelectronics Corp for 42 Days on average.
| SNY | UMC | |
|---|---|---|
Market Cap | $95.18B | $58.02B |
Volume | 2,995,646 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $52.34 | $28.02 |
52-Week Low | $39.51 | $7.02 |
Typical Hold Time | 94 Days | 42 Days |
Enterprise Value | $114.48B | $55.10B |
Dividend Yield | 6.01% | 1.76% |
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
UMC trades at $23.31, up 0.52% with a bullish technical signal despite mixed moving averages. The company shows strong profitability with 32.75% net margin and 21.03% ROE, though revenue growth has moderated from 2022 peaks. Recent earnings beats and a Zacks Strong Buy upgrade (September 17, 2026) highlight positive momentum, while cash flow turned positive in 2025 after two years of outflows.
The stock presents growth potential with expanding AI opportunities and strong 22/28nm demand, but faces risks from semiconductor cycle volatility and competitive pressures. Analyst consensus is mixed with 27% buy ratings versus 20% sell, suggesting cautious optimism amid elevated valuation multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →